Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Pre-Mkt 05-18 04:07:09 EDT

0.6705

-0.0321

-4.57%

盘前0.6545

-0.0160-2.39%

04:00 EDT

High0.7000	Low0.6501	Vol877.96K
Open0.6849	D1 Closing0.7026	Amplitude7.10%
Mkt Cap20.88M	Tradable Cap17.97M	Total Shares31.15M
T/O596.07K	T/O Rate3.28%	Tradable Shares26.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.6705,"timestamp":1778875200000,"preClose":0.7026,"halted":0,"volume":877960,"hourTrading":{"tag":"盘前","latestPrice":0.6545,"preClose":0.6705,"latestTime":"04:00 EDT","volume":1524,"amount":997.8631401600001,"timestamp":1779091226405,"change":-0.016,"changeRate":-0.023863,"amplitude":0},"delay":0,"changeRate":-0.04568744662681471,"floatShares":26803700,"shares":31146337,"eps":-1.119466,"marketStatus":"Pre-Mkt","change":-0.0321,"latestTime":"05-18 04:07:09 EDT","open":0.6849,"high":0.7,"low":0.6501,"amount":596071.0649856,"amplitude":0.071022,"askPrice":1.07,"askSize":200,"bidPrice":0.2945,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.119466,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.6705,"preHourTrading":{"tag":"盘前","latestPrice":0.6545,"preClose":0.6705,"latestTime":"04:00 EDT","volume":1524,"amount":997.8631401600001,"timestamp":1779091226405,"change":-0.016,"changeRate":-0.023863,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.6885,"preClose":0.6705,"latestTime":"19:50 EDT","volume":1712,"amount":1167.75214,"timestamp":1778889057005,"change":0.018,"changeRate":0.026846,"amplitude":0.026846},"volumeRatio":1.5488183113937446},"requestUrl":"/m/hq/s/LGVN/wiki","defaultTab":"wiki","newsList":[{"id":"2635557537","title":"Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635557537","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635557537?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:42","pubTimestamp":1778704943,"startTime":"0","endTime":"0","summary":"Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52545344/longeveron-q1-eps-0-19-misses-0-16-estimate-sales-398-000k-beat-314-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753739","title":"Longeveron Q1 revenue rises, beats analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753739","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753739?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:24","pubTimestamp":1778703879,"startTime":"0","endTime":"0","summary":"Longeveron Q1 revenue rises, beats analyst estimatesOverviewUS biotech firm's Q1 revenue rose and beat analyst expectationsNet loss for Q1 narrowed from prior yearCompany closed $30 mln private placem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q166:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758296","title":"BRIEF-Longeveron Q1 EPS USD -0.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758296","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758296?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702746,"startTime":"0","endTime":"0","summary":"BRIEF-Longeveron Q1 EPS USD -0.19\n\n\nMay 13 (Reuters) - Longeveron Q1 revenue USD 378 thousand.\n\nQ1 gross profit USD 264 thousand\nQ1 operating expenses USD 5.039 million\nQ1 income from operations USD -4.775 million\nQ1 net income USD -4.736 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXEDCA43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581997","title":"Longeveron Q1 Revenue USD 378 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581997?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXEDCA43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758067","title":"Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758067?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294435/0/en/Longeveron-Announces-2026-First-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4575","BK4150","IND","AD","BK4139","LGVN","MSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635675828","title":"Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635675828","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635675828?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:04","pubTimestamp":1778702681,"startTime":"0","endTime":"0","summary":"Longeveron posted a net loss of $4.74 million for the quarter ended March 31, 2026, narrowing 6% from a year earlier.Revenue in the quarter rose 4.46% to $398,000, while cost of revenues increased to $134,000.Operating loss improved to $4.78 million, as total operating expenses fell 7.64% to $5.04 million.Cash and cash equivalents totaled $15.8 million at March 31, 2026, with the company expecting that balance to fund operations into the fourth quarter of 2026.ELPIS II Phase 2b trial in hypoplastic left heart syndrome remains fully enrolled, with top-line results anticipated in August 2026 following an FDA Type C meeting that said right-ventricle ejection fraction is not an appropriate efficacy endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4dYj9g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237211","title":"Longeveron reports DMC approval for laromestrocel study to continue as designed","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237211?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530181,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-reports-dmc-approval-for-laromestrocel-study-to-continue-as-designed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-reports-dmc-approval-for-laromestrocel-study-to-continue-as-designed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634340442","title":"Longeveron Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634340442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634340442?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:51","pubTimestamp":1778529060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LGVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 15:51 ET (19:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823530","title":"Longeveron downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823530?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:43","pubTimestamp":1778514209,"startTime":"0","endTime":"0","summary":"Maxim downgraded Longeveron (LGVN) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-downgraded-to-hold-from-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-downgraded-to-hold-from-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634128445","title":"Longeveron DMC clears Phase 2b HLHS stem cell trial to complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2634128445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634128445?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:11","pubTimestamp":1778505068,"startTime":"0","endTime":"0","summary":"Longeveron disclosed an independent Data Monitoring Committee review that found no new safety concerns in its fully enrolled Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome, supporting completion of the study as planned.Results have not yet been presented; top-line data are expected in August 2026.Review outcome reduces near-term clinical hold risk, keeping a key rare-disease program on track ahead of a pivotal readout.Trial enrolled 40 pediatric patients across 12 US cardiac centers, with NIH-backed funding support cited for the study.Laromestrocel holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for hypoplastic left heart syndrome, which could support an accelerated regulatory path if efficacy data are positive.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4d2DrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4588","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LGVN","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","BK4139","SG9999014021.USD","LU0314104364.USD","BK4585","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284924","title":"Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284924?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:10","pubTimestamp":1778505000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5XCLZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284120","title":"Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284120?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:10","pubTimestamp":1778505000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5XCLZD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634228412","title":"Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2634228412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634228412?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:10","pubTimestamp":1778505000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5XCLZD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634984384","title":"Longeveron provides update on laromestrocel development after Type C meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2634984384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634984384?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:59","pubTimestamp":1778281158,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that a constructive Type C meeting with the FDA was held in late March, with the FDA providing their meeting summary in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-provides-update-on-laromestrocel-development-after-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-provides-update-on-laromestrocel-development-after-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN","BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634460352","title":"Longeveron Updates FDA Path for ELPIS II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460352","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634460352?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:24","pubTimestamp":1778275499,"startTime":"0","endTime":"0","summary":"An update from Longeveron ( ($LGVN) ) is now available. On May 8, 2026, Longeveron reported that a Type C meeting held with the U.S. Food and Drug ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-updates-fda-path-for-elpis-ii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-updates-fda-path-for-elpis-ii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4585","BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462251","title":"Longeveron Says the FDA No Longer Sees Trial for Heart Syndrome Treatment as Pivotal","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462251","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462251?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:42","pubTimestamp":1778272920,"startTime":"0","endTime":"0","summary":"Longeveron said the Food and Drug Administration no longer refers to its Phase 2b clinical trial for a potential treatment for hypoplastic left heart syndrome  as pivotal.The biotechnology company said Friday the two parties did not land on an appropriate primary endpoint for the study in their Type C meeting in March. The FDA indicated the study's primary endpoint of right ventricle ejection fraction is not an appropriate endpoint to demonstrate efficacy, and indicated that the two parties would not be able to agree on a new primary endpoint while the trial remains ongoing given an interim analysis mandated and conducted by the National Institute of Health.However, Longeveron said the FDA indicated it is willing to meet again when the study is complete to discuss the results and align on a potential path forward. During the Type C meeting, the FDA acknowledged that HLHS is a rare disease associated with significant morbidity and mortality with a high unmet medical need for safe and ef","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","LGVN","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634640674","title":"Longeveron targets August ELPIS II Phase 2b HLHS data readout for laromestrocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2634640674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634640674?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:21","pubTimestamp":1778271670,"startTime":"0","endTime":"0","summary":"Longeveron disclosed a Type C meeting with FDA that reset regulatory expectations for laromestrocel in its ongoing Phase 2b ELPIS II study in hypoplastic left heart syndrome.FDA rejected right ventricle ejection fraction as suitable primary endpoint to support efficacy, leaving trial without an agreed endpoint that could underpin a pivotal program while study remains ongoing.Agency no longer characterizes ELPIS II as pivotal, raising execution risk for near-term BLA strategy despite continued openness to reassess path forward once study completes.Top-line ELPIS II results have not been presented yet; readout remains expected in August 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content us","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL2wGHW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634464575","title":"Longeveron Inc - FDA Says New Primary Endpoint for Elpis Ii Cannot Be Agreed While Trial Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634464575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634464575?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:05","pubTimestamp":1778270700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA461KHS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634464503","title":"Longeveron Announces Constructive Type C Meeting With U.S. FDA Ahead of Data Readout for Elpis Ii Phase 2B Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (Hlhs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634464503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634464503?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:05","pubTimestamp":1778270700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA461KHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633247559","title":"Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633247559","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633247559?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:15","pubTimestamp":1778012100,"startTime":"0","endTime":"0","summary":"MIAMI, May  05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288288/0/en/Longeveron-to-Report-2026-First-Quarter-Financial-Results-and-Host-Conference-Call-on-May-13-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MSC","AD","BK4575","LGVN","BK4150","BK4218","BK4181","BK4585","BK4139","HST","BK4132"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.2067},{"period":"1month","weight":-0.4013},{"period":"3month","weight":0.2514},{"period":"6month","weight":-0.0164},{"period":"1year","weight":-0.5211},{"period":"ytd","weight":0.3251}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052773},{"month":3,"riseRate":0.5,"avgChangeRate":0.193379},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.138428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.152903},{"month":6,"riseRate":0.8,"avgChangeRate":0.122312},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}